{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T15:46:40Z","timestamp":1791820000472,"version":"4.3.4"},"reference-count":79,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2020,5,19]],"date-time":"2020-05-19T00:00:00Z","timestamp":1589846400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAD"],"published-print":{"date-parts":[[2020,5,19]]},"DOI":"10.3233\/jad-191173","type":"journal-article","created":{"date-parts":[[2020,4,10]],"date-time":"2020-04-10T11:54:42Z","timestamp":1586519682000},"page":"501-519","source":"Crossref","is-referenced-by-count":34,"title":["Concentration-Dependent Activity of Hydromethylthionine on Clinical Decline and Brain Atrophy in a Randomized Controlled Trial in Behavioral Variant Frontotemporal Dementia"],"prefix":"10.1177","volume":"75","author":[{"given":"Helen","family":"Shiells","sequence":"first","affiliation":[{"name":"TauRx Therapeutics Ltd., Aberdeen, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bjoern O.","family":"Schelter","sequence":"additional","affiliation":[{"name":"TauRx Therapeutics Ltd., Aberdeen, UK"},{"name":"Institute for Complex Systems and Mathematical Biology, University of Aberdeen, Aberdeen, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Bentham","sequence":"additional","affiliation":[{"name":"TauRx Therapeutics Ltd., Aberdeen, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas C.","family":"Baddeley","sequence":"additional","affiliation":[{"name":"TauRx Therapeutics Ltd., Aberdeen, UK"},{"name":"Department of Chemistry, University of Aberdeen, Aberdeen, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher M.","family":"Rubino","sequence":"additional","affiliation":[{"name":"Institute of Clinical Pharmacodynamics, Schenectady, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harish","family":"Ganesan","sequence":"additional","affiliation":[{"name":"Institute of Clinical Pharmacodynamics, Schenectady, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Hammel","sequence":"additional","affiliation":[{"name":"Institute of Clinical Pharmacodynamics, Schenectady, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vesna","family":"Vuksanovic","sequence":"additional","affiliation":[{"name":"Aberdeen Biomedical Imaging Centre, School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Aberdeen, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger T.","family":"Staff","sequence":"additional","affiliation":[{"name":"Aberdeen Royal Infirmary, NHS Grampian, Aberdeen, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison D.","family":"Murray","sequence":"additional","affiliation":[{"name":"Aberdeen Biomedical Imaging Centre, School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Aberdeen, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc","family":"Bracoud","sequence":"additional","affiliation":[{"name":"Bioclinica, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damon J.","family":"Wischik","sequence":"additional","affiliation":[{"name":"TauRx Therapeutics Ltd., Aberdeen, UK"},{"name":"Department of Computer Science and Technology, University of Cambridge, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gernot","family":"Riedel","sequence":"additional","affiliation":[{"name":"School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Foresterhill, Aberdeen, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serge","family":"Gauthier","sequence":"additional","affiliation":[{"name":"McGill Centre for Studies in Aging, Alzheimer\u2019s Disease Research Unit, and Douglas Mental Health University Institute, Montreal, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianping","family":"Jia","sequence":"additional","affiliation":[{"name":"Beijing Institute for Brain Disorders Alzheimer\u2019s Disease Centre, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans J.","family":"Moebius","sequence":"additional","affiliation":[{"name":"Moebius-Consult, Baar, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiri","family":"Hardlund","sequence":"additional","affiliation":[{"name":"TauRx Therapeutics Ltd., Aberdeen, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher M.","family":"Kipps","sequence":"additional","affiliation":[{"name":"University Hospital Southampton and University of Southampton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Kook","sequence":"additional","affiliation":[{"name":"Salamandra LLC, Bethesda, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.D.","family":"Storey","sequence":"additional","affiliation":[{"name":"TauRx Therapeutics Ltd., Aberdeen, UK"},{"name":"Department of Chemistry, University of Aberdeen, Aberdeen, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles R.","family":"Harrington","sequence":"additional","affiliation":[{"name":"TauRx Therapeutics Ltd., Aberdeen, UK"},{"name":"School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Foresterhill, Aberdeen, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claude M.","family":"Wischik","sequence":"additional","affiliation":[{"name":"TauRx Therapeutics Ltd., Aberdeen, UK"},{"name":"School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Foresterhill, Aberdeen, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","reference":[{"key":"10.3233\/JAD-191173_ref1","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1093\/brain\/awr179","article-title":"Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia","volume":"134","author":"Rascovsky","year":"2011","journal-title":"Brain"},{"key":"10.3233\/JAD-191173_ref2","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1212\/WNL.0000000000002638","article-title":"Prevalence, characteristics, and survival of frontotemporal lobar degeneration syndromes","volume":"86","author":"Coyle-Gilchrist","year":"2016","journal-title":"Neurology"},{"key":"10.3233\/JAD-191173_ref3","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.ncl.2017.01.008","article-title":"Frontotemporal dementia","volume":"35","author":"Olney","year":"2017","journal-title":"Neurol Clin"},{"key":"10.3233\/JAD-191173_ref4","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s12883-018-1060-1","article-title":"The behavioural variant frontotemporal dementia phenocopy syndrome is a distinct entity - evidence from a longitudinal study","volume":"18","author":"Devenney","year":"2018","journal-title":"BMC Neurol"},{"key":"10.3233\/JAD-191173_ref5","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1097\/WCO.0b013e3283404309","article-title":"Nonprogressive behavioural frontotemporal dementia: recent developments and clinical implications of the \u2018bvFTD phenocopy syndrome\u2019","volume":"23","author":"Kipps","year":"2010","journal-title":"Curr Opin Neurol"},{"key":"10.3233\/JAD-191173_ref6","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1136\/jnnp.2008.163873","article-title":"Can progressive and non-progressive behavioural variant frontotemporal dementia be distinguished at presentation?","volume":"80","author":"Hornberger","year":"2009","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.3233\/JAD-191173_ref7","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1212\/01.wnl.0000171343.43314.6e","article-title":"Rate of progression differs in frontotemporal dementia and Alzheimer disease","volume":"65","author":"Rascovsky","year":"2005","journal-title":"Neurology"},{"key":"10.3233\/JAD-191173_ref8","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1159\/000443205","article-title":"Survival in frontotemporal dementia phenotypes: a meta-analysis","volume":"41","author":"Kansal","year":"2016","journal-title":"Dement Geriatr Cogn Disord"},{"key":"10.3233\/JAD-191173_ref9","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1097\/WAD.0b013e318247a0bc","article-title":"The impact of dementia severity on caregiver burden in frontotemporal dementia and Alzheimer disease","volume":"27","author":"Mioshi","year":"2013","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"10.3233\/JAD-191173_ref10","doi-asserted-by":"crossref","first-page":"e190261","DOI":"10.1001\/jamanetworkopen.2019.0261","article-title":"Association of neuropathologically confirmed frontotemporal dementia and Alzheimer disease with criminal and socially inappropriate behavior in a Swedish cohort","volume":"2","author":"Liljegren","year":"2019","journal-title":"JAMA Netw Open"},{"key":"10.3233\/JAD-191173_ref11","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1017\/cjn.2016.36","article-title":"The prevalence and incidence of dementia due to Alzheimer\u2019s disease: a systematic review and meta-analysis","volume":"43","author":"Fiest","year":"2016","journal-title":"Can J Neurol Sci"},{"key":"10.3233\/JAD-191173_ref12","doi-asserted-by":"crossref","first-page":"S96","DOI":"10.1017\/cjn.2016.25","article-title":"The prevalence and incidence of frontotemporal dementia: a systematic review","volume":"43","author":"Hogan","year":"2016","journal-title":"Can J Neurol Sci"},{"key":"10.3233\/JAD-191173_ref13","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1212\/WNL.0000000000004614","article-title":"The social and economic burden of frontotemporal degeneration","volume":"89","author":"Galvin","year":"2017","journal-title":"Neurology"},{"key":"10.3233\/JAD-191173_ref14","first-page":"CD009444","article-title":"Cholinesterase inhibitors for rarer dementias associated with neurological conditions","author":"Li","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"10.3233\/JAD-191173_ref15","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1159\/000113034","article-title":"Galantamine in frontotemporal dementia and primary progressive aphasia","volume":"25","author":"Kertesz","year":"2008","journal-title":"Dement Geriatr Cogn Disord"},{"key":"10.3233\/JAD-191173_ref16","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1111\/j.1447-0594.2012.00956.x","article-title":"Pilot study of pharmacological treatment for frontotemporal dementia: risk of donepezil treatment for behavioral and psychological symptoms","volume":"13","author":"Kimura","year":"2013","journal-title":"Geriatr Gerontol Int"},{"key":"10.3233\/JAD-191173_ref17","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s40266-019-00685-6","article-title":"Use of cholinesterase inhibitors in non-Alzheimer\u2019s dementias","volume":"36","author":"Noufi","year":"2019","journal-title":"Drugs Aging"},{"key":"10.3233\/JAD-191173_ref18","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S1474-4422(12)70320-4","article-title":"Memantine in patients with frontotemporal lobar degeneration: a multicentre, randomised, double-blind, placebo-controlled trial","volume":"12","author":"Boxer","year":"2013","journal-title":"Lancet Neurol"},{"key":"10.3233\/JAD-191173_ref19","doi-asserted-by":"crossref","first-page":"749","DOI":"10.3233\/JAD-2010-101632","article-title":"Memantine in behavioral variant frontotemporal dementia: negative results","volume":"23","author":"Vercelletto","year":"2011","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-191173_ref20","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1159\/000077171","article-title":"Frontotemporal dementia: a randomised, controlled trial with trazodone","volume":"17","author":"Lebert","year":"2004","journal-title":"Dement Geriatr Cogn Disord"},{"key":"10.3233\/JAD-191173_ref21","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1093\/brain\/awn234","article-title":"Development of methodology for conducting clinical trials in frontotemporal lobar degeneration","volume":"131","author":"Knopman","year":"2008","journal-title":"Brain"},{"key":"10.3233\/JAD-191173_ref22","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1146\/annurev-neuro-072116-031153","article-title":"Propagation of tau aggregates and neurodegeneration","volume":"40","author":"Goedert","year":"2017","journal-title":"Ann Rev Neurosci"},{"key":"10.3233\/JAD-191173_ref23","doi-asserted-by":"crossref","first-page":"3329","DOI":"10.1093\/brain\/awx254","article-title":"Clinicopathological correlations in behavioural variant frontotemporal dementia","volume":"140","author":"Perry","year":"2017","journal-title":"Brain"},{"key":"10.3233\/JAD-191173_ref24","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.jalz.2016.03.018","article-title":"Tau: From research to clinical development","volume":"12","author":"Holtzman","year":"2016","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-191173_ref25","doi-asserted-by":"crossref","first-page":"10862","DOI":"10.1074\/jbc.M114.616029","article-title":"Cellular models of aggregation-dependent template-directed proteolysis to characterize tau aggregation inhibitors for treatment of Alzheimer\u2019s disease","volume":"290","author":"Harrington","year":"2015","journal-title":"J Biol Chem"},{"key":"10.3233\/JAD-191173_ref26","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1124\/jpet.114.219352","article-title":"Complex disposition of methylthioninium redox forms determines efficacy in tau aggregation inhibitor therapy for Alzheimer\u2019s disease","volume":"352","author":"Baddeley","year":"2015","journal-title":"J Pharmacol Exp Ther"},{"key":"10.3233\/JAD-191173_ref27","doi-asserted-by":"crossref","first-page":"4119","DOI":"10.1016\/j.jmb.2018.08.010","article-title":"Cysteine-independent inhibition of Alzheimer\u2019s disease-like paired helical filament assembly by leuco-methylthioninium (LMT)","volume":"430","author":"Al-Hilaly","year":"2018","journal-title":"J Mol Biol"},{"key":"10.3233\/JAD-191173_ref28","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/s41586-018-0454-y","article-title":"Structures of filaments from Pick\u2019s disease reveal a novel tau protein fold","volume":"561","author":"Falcon","year":"2018","journal-title":"Nature"},{"key":"10.3233\/JAD-191173_ref29","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/nature23002","article-title":"Cryo-EM structures of tau filaments from Alzheimer\u2019s disease","volume":"547","author":"Fitzpatrick","year":"2017","journal-title":"Nature"},{"key":"10.3233\/JAD-191173_ref30","doi-asserted-by":"crossref","first-page":"4884","DOI":"10.1073\/pnas.85.13.4884","article-title":"Structural characterization of the core of the paired helical filament of Alzheimer disease","volume":"85","author":"Wischik","year":"1988","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.3233\/JAD-191173_ref31","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/FBP.0000000000000133","article-title":"Effects of oxidized and reduced forms of methylthioninium in two transgenic mouse tauopathy models","volume":"26","author":"Melis","year":"2015","journal-title":"Behav Pharmacol"},{"key":"10.3233\/JAD-191173_ref32","doi-asserted-by":"crossref","first-page":"609","DOI":"10.4161\/auto.19048","article-title":"Methylthioninium chloride (methylene blue) induces autophagy and attenuates tauopathy in vitro and in vivo","volume":"8","author":"Congdon","year":"2012","journal-title":"Autophagy"},{"key":"10.3233\/JAD-191173_ref33","doi-asserted-by":"crossref","first-page":"11213","DOI":"10.1073\/pnas.93.20.11213","article-title":"Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines","volume":"93","author":"Wischik","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.3233\/JAD-191173_ref34","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1016\/j.febslet.2009.06.042","article-title":"Methylene blue and dimebon inhibit aggregation of TDP-43 in cellular models","volume":"583","author":"Yamashita","year":"2009","journal-title":"FEBS Lett"},{"key":"10.3233\/JAD-191173_ref35","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.neuroscience.2011.12.047","article-title":"Methylene blue administration fails to confer neuroprotection in two amyotrophic lateral sclerosis mouse models","volume":"209","author":"Audet","year":"2012","journal-title":"Neuroscience"},{"key":"10.3233\/JAD-191173_ref36","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/biof.197","article-title":"Mitochondrial pharmacology: electron transport chain bypass as strategies to treat mitochondrial dysfunction","volume":"38","author":"Atamna","year":"2012","journal-title":"Biofactors"},{"key":"10.3233\/JAD-191173_ref37","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1096\/fj.07-9610com","article-title":"Methylene blue delays cellular senescence and enhances key mitochondrial biochemical pathways","volume":"22","author":"Atamna","year":"2008","journal-title":"FASEB J"},{"key":"10.3233\/JAD-191173_ref38","doi-asserted-by":"publisher","DOI":"10.2174\/1567205017666200224120926"},{"key":"10.3233\/JAD-191173_ref39","doi-asserted-by":"crossref","first-page":"3716","DOI":"10.1093\/hmg\/ddu080","article-title":"Methylene blue upregulates Nrf2\/ARE genes and prevents tau-related neurotoxicity","volume":"23","author":"Stack","year":"2014","journal-title":"Hum Mol Genet"},{"key":"10.3233\/JAD-191173_ref40","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3892\/mmr.2015.4551","article-title":"Methylene blue exerts a neuroprotective effect against traumatic brain injury by promoting autophagy and inhibiting microglial activation","volume":"13","author":"Zhao","year":"2016","journal-title":"Mol Med Rep"},{"key":"10.3233\/JAD-191173_ref41","doi-asserted-by":"crossref","first-page":"203","DOI":"10.3389\/fnmol.2019.00203","article-title":"Targeting autophagy for the treatment of Alzheimer\u2019s disease: challenges and opportunities","volume":"12","author":"Liu","year":"2019","journal-title":"Front Mol Neurosci"},{"key":"10.3233\/JAD-191173_ref42","doi-asserted-by":"crossref","first-page":"963","DOI":"10.3389\/fnins.2018.00963","article-title":"Molecular mechanisms of synaptotoxicity and neuroinflammation in Alzheimer\u2019s disease","volume":"12","author":"Marttinen","year":"2018","journal-title":"Front Neurosci"},{"key":"10.3233\/JAD-191173_ref43","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1146\/annurev-med-042915-103753","article-title":"Update on Alzheimer\u2019s disease therapy and prevention strategies","volume":"68","author":"Graham","year":"2017","journal-title":"Ann Rev Med"},{"key":"10.3233\/JAD-191173_ref44","doi-asserted-by":"crossref","first-page":"435","DOI":"10.3233\/JAD-170560","article-title":"Potential of low dose leuco-methylthioninium bis(hydromethanesulphonate) (LMTM) monotherapy for treatment of mild Alzheimer\u2019s disease: cohort analysis as modified primary outcome in a phase 3 clinical trial","volume":"61","author":"Wilcock","year":"2018","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-191173_ref45","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1016\/S0140-6736(16)31275-2","article-title":"Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer\u2019s disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial","volume":"388","author":"Gauthier","year":"2016","journal-title":"Lancet"},{"key":"10.3233\/JAD-191173_ref46","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/jps.2600610710","article-title":"Pharmacokinetics of highly ionized drugs. II. Methylene blue - absorption, metabolism, and excretion in man and dog after oral administration","volume":"61","author":"DiSanto","year":"1972","journal-title":"J Pharm Sci"},{"key":"10.3233\/JAD-191173_ref47","doi-asserted-by":"crossref","first-page":"705","DOI":"10.3233\/JAD-142874","article-title":"Tau aggregation inhibitor therapy: an exploratory phase 2 study in mild or moderate Alzheimer\u2019s disease","volume":"44","author":"Wischik","year":"2015","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-191173_ref48","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jchromb.2008.01.028","article-title":"Quantification of cationic anti-malaria agent methylene blue in different human biological matrices using cation exchange chromatography coupled to tandem mass spectrometry","volume":"863","author":"Burhenne","year":"2008","journal-title":"J Chromatog B"},{"key":"10.3233\/JAD-191173_ref49","doi-asserted-by":"crossref","first-page":"931","DOI":"10.3233\/JAD-190772","article-title":"Concentration-dependent activity of hydromethylthionine on cognitive decline and brain atrophy in mild to moderate Alzheimer\u2019s disease","volume":"72","author":"Schelter","year":"2019","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-191173_ref50","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1097\/WAD.0b013e31815c3445","article-title":"Diagnostic criteria for the behavioral variant of frontotemporal dementia (bvFTD): Current limitations and future directions","volume":"21","author":"Rascovsky","year":"2007","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"10.3233\/JAD-191173_ref51","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1212\/01.wnl.0000313366.76973.8a","article-title":"Measuring progression in frontotemporal dementia: Implications for therapeutic interventions","volume":"70","author":"Kipps","year":"2008","journal-title":"Neurology"},{"key":"10.3233\/JAD-191173_ref52","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1002\/gps.1610","article-title":"The Addenbrooke\u2019s Cognitive Examination Revised (ACE-R): a brief cognitive test battery for dementia screening","volume":"21","author":"Mioshi","year":"2006","journal-title":"Int J Geriatr Psychiatry"},{"key":"10.3233\/JAD-191173_ref53","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1093\/geronj\/37.3.323","article-title":"Measurement of functional activities in older adults in the community","volume":"37","author":"Pfeffer","year":"1982","journal-title":"J Gerontol"},{"key":"10.3233\/JAD-191173_ref54","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1212\/WNL.0b013e3181e04070","article-title":"Clinical staging and disease progression in frontotemporal dementia","volume":"74","author":"Mioshi","year":"2010","journal-title":"Neurology"},{"key":"10.3233\/JAD-191173_ref55","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1159\/000351671","article-title":"Validation of the Addenbrooke\u2019s Cognitive Examination III in frontotemporal dementia and Alzheimer\u2019s disease","volume":"36","author":"Hsieh","year":"2013","journal-title":"Dement Geriatr Cogn Disord"},{"key":"10.3233\/JAD-191173_ref56","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1002\/jmri.1880070620","article-title":"Brain atrophy progression measured from registered serial MRI: Validation and application to Alzheimer\u2019s disease","volume":"7","author":"Fox","year":"1997","journal-title":"J Magn Reson Imaging"},{"key":"10.3233\/JAD-191173_ref57","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1016\/j.neurobiolaging.2010.11.001","article-title":"Gray matter atrophy rate as a marker of disease progression in AD","volume":"33","author":"Anderson","year":"2012","journal-title":"Neurobiol Aging"},{"key":"10.3233\/JAD-191173_ref58","first-page":"153","volume-title":"Recent Developments in Parkinson\u2019s Disease","author":"Fahn","year":"1987"},{"key":"10.3233\/JAD-191173_ref60","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1056\/NEJMra041867","article-title":"The serotonin syndrome","volume":"352","author":"Boyer","year":"2005","journal-title":"N Eng J Med"},{"key":"10.3233\/JAD-191173_ref61","first-page":"215","article-title":"Methylene blue encephalopathy: a case report and review of published cases","volume":"81","author":"Shopes","year":"2013","journal-title":"Am Assoc Nurse Anesth J"},{"key":"10.3233\/JAD-191173_ref62","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/0022-5193(68)90188-4","article-title":"Kinetics of pharmacologic response I. Proposed relationships between response and drug concentration in the intact animal and man","volume":"20","author":"Wagner","year":"1968","journal-title":"J Theor Biol"},{"key":"10.3233\/JAD-191173_ref63","doi-asserted-by":"crossref","first-page":"1850055","DOI":"10.1142\/S0129065718500557","article-title":"Cortical thickness and surface area networks in healthy aging, Alzheimer\u2019s disease and behavioral variant fronto-temporal dementia","volume":"29","author":"Vuksanovi\u0107","year":"2019","journal-title":"Int J Neural Syst"},{"key":"10.3233\/JAD-191173_ref64","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1176\/ajp.148.6.705","article-title":"The serotonin syndrome","volume":"148","author":"Sternbach","year":"1991","journal-title":"Am J Psychiatry"},{"key":"10.3233\/JAD-191173_ref65","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1093\/qjmed\/hcg109","article-title":"The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity","volume":"96","author":"Dunkley","year":"2003","journal-title":"QJM"},{"key":"10.3233\/JAD-191173_ref66","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1093\/brain\/awz099","article-title":"Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report","volume":"142","author":"Nelson","year":"2019","journal-title":"Brain"},{"key":"10.3233\/JAD-191173_ref67","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/BF00296179","article-title":"Quantitative neuropathologic analysis of Pick\u2019s disease cases: cortical distribution of Pick bodies and coexistence with Alzheimer\u2019s disease","volume":"87","author":"Hof","year":"1994","journal-title":"Acta Neuropathol"},{"key":"10.3233\/JAD-191173_ref68","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/ana.20366","article-title":"Pick bodies in a family with presenilin-1 Alzheimer\u2019s disease","volume":"57","author":"Halliday","year":"2005","journal-title":"Ann Neurol"},{"key":"10.3233\/JAD-191173_ref69","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1523\/JNEUROSCI.07-06-01799.1987","article-title":"Laminar and regional distributions of neurofibrillary tangles and neuritic plaques in Alzheimer\u2019s disease: a quantitative study of visual and auditory cortices","volume":"7","author":"Lewis","year":"1987","journal-title":"J Neurosci"},{"key":"10.3233\/JAD-191173_ref70","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/nyas.13870","article-title":"Methylene blue protects dopaminergic neurons against MPTP-induced neurotoxicity by upregulating brain-derived neurotrophic factor","volume":"1431","author":"Bhurtel","year":"2018","journal-title":"Ann N Y Acad Sci"},{"key":"10.3233\/JAD-191173_ref71","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1046\/j.1440-1789.2001.00402.x","article-title":"Neurotoxicity of MPTP","volume":"21","author":"Fukuda","year":"2001","journal-title":"Neuropathology"},{"key":"10.3233\/JAD-191173_ref72","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1038\/sj.bjp.0707430","article-title":"Methylene blue and serotonin toxicity: inhibition of monoamine oxidase A (MAO A) confirms a theoretical prediction","volume":"152","author":"Ramsay","year":"2007","journal-title":"Br J Pharmacol"},{"key":"10.3233\/JAD-191173_ref73","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/j.1476-5381.2011.01462.x","article-title":"Methylene blue inhibits function of the 5-HT transporter","volume":"166","author":"Oz","year":"2012","journal-title":"Br J Pharmacol"},{"key":"10.3233\/JAD-191173_ref74","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1212\/WNL.51.6.1546","article-title":"Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria","volume":"51","author":"Neary","year":"1998","journal-title":"Neurology"},{"key":"10.3233\/JAD-191173_ref75","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1093\/brain\/awy319","article-title":"Longitudinal multimodal imaging and clinical endpoints for frontotemporal dementia clinical trials","volume":"142","author":"Staffaroni","year":"2019","journal-title":"Brain"},{"key":"10.3233\/JAD-191173_ref76","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1212\/WNL.0b013e3181a71236","article-title":"Brain and ventricular volumetric changes in frontotemporal lobar degeneration over 1 year","volume":"72","author":"Knopman","year":"2009","journal-title":"Neurology"},{"key":"10.3233\/JAD-191173_ref77","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jalz.2019.06.4956","article-title":"New directions in clinical trials for frontotemporal lobar degeneration: Methods and outcome measures","volume":"16","author":"Boxer","year":"2020","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-191173_ref78","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1136\/jnnp-2018-318603","article-title":"Therapeutic trial design for frontotemporal dementia and related disorders","volume":"90","author":"Desmarais","year":"2019","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.3233\/JAD-191173_ref79","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1212\/WNL.0b013e318296e940","article-title":"Dissociable executive functions in behavioral variant frontotemporal and Alzheimer dementias","volume":"80","author":"Possin","year":"2013","journal-title":"Neurology"},{"key":"10.3233\/JAD-191173_ref80","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1177\/1073858411410354","article-title":"Frontotemporal dementia: what can the behavioral variant teach us about human brain organization?","volume":"18","author":"Seeley","year":"2012","journal-title":"Neuroscientist"}],"container-title":["Journal of Alzheimer's Disease"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JAD-191173","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T10:07:59Z","timestamp":1777370879000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JAD-191173"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,19]]},"references-count":79,"journal-issue":{"issue":"2"},"URL":"https:\/\/doi.org\/10.3233\/jad-191173","relation":{},"ISSN":["1387-2877","1875-8908"],"issn-type":[{"value":"1387-2877","type":"print"},{"value":"1875-8908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,19]]}}}